6 stories mentioning HKG:3933Updated 11d ago
Every FINWIRES story that references HKG:3933, newest first.
United Laboratories International (HKG:3933) wholly owned subsidiary, Zhuhai United Laboratories, received approval from China's National Medical Products Administration to begin clinical trials of TUL321 capsules, according to a Thursday Hong Kong bourse filing.TUL321 is a next-generation complement factor B inhibitor being developed for autoimmune and complement-mediated diseases, the filing said.
The United Laboratories International (HKG:3933) plans to repurchase up to HK$200 million of its shares on the open market under a shareholder-approved mandate, according to a Thursday Hong Kong bourse filing.The company said the buyback will be funded by internal cash resources, and shares repurchased under the plan will be canceled.
The United Laboratories International (HKG:3933) unit Zhuhai United Laboratories obtained approval for the clinical trial of TUL108 for Injection from China's National Medical Products Administration, according to a Tuesday Hong Kong bourse filing.The drug is intended to treat infections caused by Gram-negative or Gram-positive bacteria, including complicated urinary tract infections, complicated intra-abdominal infections, pulmonary infections, and bloodstream infections.
The United Laboratories International (HKG:3933) said Thursday a subsidiary's clinical trial application for its long-acting weekly insulin product secured approval in China.Specifically, China's National Medical Products Administration cleared the testing for United Bio-Technology (Hengqing)'s UBT38006 injection.
The United Laboratories International (HKG:3933) unit Zhuhai United Laboratories obtained approval for the new drug application of its TUL321 Capsules from the US Food and Drug Administration (FDA), according to a Tuesday Hong Kong bourse filing.The FDA also accepted an application for the clinical trial registration of the drug.The drug is intended to be used in the treatment of paroxysmal nocturnal hemoglobinuria (PNH), IgA nephropathy, age-related macular degeneration, multiple sclerosis, and myasthenia gravis.
The United Laboratories International (HKG:3933) unit Zhuhai United Bio-Pharmaceutical obtained approval for a clinical trial of dupilumab bio-similar from China's National Medical Products Administration, according to a Wednesday Hong Kong bourse filing.The approved indication is for atopic dermatitis.
